Compare W W Grainger Inc (GWW) vs Johnson & Johnson (JNJ) Price & Performance

GWW trades at $1,391.07, up 1.46% with strong technical momentum and bullish moving averages. The company reported solid Q1 2026 earnings of $11.65 per share, beating estimates, and raised full-year guidance. With revenue growth to $18.4B and net profit margin improving to 9.69%, fundamentals remain robust despite elevated valuation multiples.

Outlook remains positive with analyst consensus price target of $1,260 offering modest upside. Key risks include high P/E ratio of 36.88 and competitive pressures in industrial distribution. The stock presents a quality growth opportunity but requires monitoring of valuation sustainability amid economic uncertainties.

Johnson & Johnson (JNJ) trades at $249.42, down 1.75% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q2 2026 EPS of $2.90, beating estimates, and raised full-year guidance. Revenue grew 6.6% annually, supported by strong pharmaceutical sales. Analyst consensus is bullish with a $281 price target, and the stock offers a stable dividend with recent payouts of $1.34 per share.

Outlook remains positive due to robust fundamentals, innovation in medtech and pharmaceuticals, and dividend king status. Risks include patent expirations, regulatory pressures, and macroeconomic volatility. The current valuation at P/E 28.66 may limit near-term upside, but long-term growth prospects appear solid.